

Fig. 1. ALP-specific activities of the duodenum (A), jejunum (B), and ileum (C). Results are the mean  $\pm$  SE of 7 animals. Significant difference between the MK and control groups ( $*p < 0.05$ ). D: Mouse intestinal ALP isozymes separated by polyacrylamide gel electrophoresis. The gels were stained for ALP activity with a  $\beta$ -naphthyl-phosphoric acid monosodium salt, Fast violet B salt. Cont.: control, PK: phyloquinone, MK: menaquinone-4.

**Statistical analyses.** Values are shown as the mean  $\pm$  standard error (SE).

Dunnett's multiple comparison test was used after ANOVA to compare the significance of differences among the control and PK or MK. Differences were considered significant at  $p < 0.05$ . Analysis was conducted using SPSS 18.0J (SPSS, Inc., Chicago, IL, USA).

## RESULTS

### ALP activity

To examine whether IAP was secreted from the intestinal mucosa on the oral administration of PK or MK, we measured the levels of serum ALP activity (mU/mL) in the control, PK, and MK groups, being  $13.7 \pm 1.2$ ,  $10.3 \pm 2.0$ , and  $14.1 \pm 1.8$  (mean  $\pm$  SE), respectively, showing no significant differences among these groups.

ALP-specific activities in the intestine are shown in Fig. 1. There were no significant differences in ALP activities among these groups in the duodenum (Fig. 1A) and ileum (Fig. 1C). As presented in Fig. 1B, ALP activity of the MK group in the jejunum was significantly higher compared with the control group ( $p < 0.05$ ).

### Molecular weight determination by SDS-PAGE

The molecular weights of ALPs of each intestinal segment were estimated employing SDS-PAGE analysis. As shown in Fig. 1D, the 110-kDa band of the major ALP isozyme was detected in the duodenum among these groups. In the jejunum, ALP enzymes were separated into two bands of 110 and 90 kDa, and the intensity of their enzymatic activity increased markedly in both PK and MK groups, similarly to the results regarding the specific ALP activity in the jejunum. In the distal part of

Table 1. Inhibitory effects of levamisole, L-phenylalanine and heat inactivation of ALP preparations of the jejunum.

Groups	Relative activity(%)		
	Levamisole (1 mM)	L-Phenylalanine (20 mM)	Heat inactivation (60°C 10 min)
Cont.	95.2 $\pm$ 1.6	23.0 $\pm$ 1.0	42.4 $\pm$ 3.4
PK	94.2 $\pm$ 2.1	23.5 $\pm$ 1.4	46.1 $\pm$ 2.3
MK	95.5 $\pm$ 1.6	24.2 $\pm$ 2.0	45.9 $\pm$ 2.5

Each value represents mean  $\pm$  SE ( $n = 7$ ).

The ALP activity was assayed based on the rate of *p*-NPP hydrolysis. The effect of the inhibitor was determined in the presence of 5 mM MgCl<sub>2</sub> in the assay mixture. Remaining ALP activity with inhibitors or after heat treatment is expressed as a percent of non-treated controls. Results are the mean  $\pm$  SE of 7 animals.

the intestine (ileum), the ALP isozyme showed a main band of 90 kDa among these groups. No additional band was observed in any intestinal samples among the groups.

### Properties of ALP in the intestine

The enzymatic properties of ALP preparations of the jejunum which increased significantly on PK or MK administration were investigated employing an inhibition experiment with levamisole (Lev) and L-phenylalanine (L-Phe) and through a thermo-stability test. It is well known that IAP activity is not inhibited by Lev and is more stable to L-Phe and more heat-stable than TNSALP. As shown in Table 1, there was no significant




Fig. 2. Detection by RT-PCR of mRNAs for *Akp3*, *Akp6*, PXR, and GAPDH in the duodenum, jejunum, and ileum. PCR products were electrophoresed in a 5.25% polyacrylamide gel. Cont.: control, PK: phylloquinone, MK: menaquinone-4.

difference in the relative activities among these groups. We confirmed that these jejunum ALP preparations were effectively inhibited by L-Phe but not by Lev, and were heat-stable (60°C, 10 min), corresponding to the property of other mammalian intestinal type ALPs.

#### RT-PCR analysis of ALP mRNA expression

RT-PCR-based detections of mRNA for *Akp3*, *Akp6*, and PXR in the duodenum, jejunum, and ileum are shown in Fig. 2. The PCR products of *Akp3* (335 bp) were detected in the duodenum and jejunum. The PCR products of *Akp6* (473 bp) were detected in the duodenum, jejunum, and ileum. The PCR products of PXR (602 bp) were detected in the duodenum, jejunum, and ileum. The intensities of mRNA expression of *Akp3* and *Akp6* were very similar both in the duodenum and ileum among the three groups (Cont., PK, and MK groups). The intensities of mRNA expression of *Akp3*, *Akp6*, and PXR were enhanced in both the PK and MK groups compared with the control group in the jejunum.

PCR products of *Akp2* (198 bp) and *Akp5* (500 bp) were not detected in any of these intestinal samples.

In order to compare these intensities of mRNA expression in the jejunum, we determined the relative density of the PCR products of the mouse jejunum. As shown in Fig. 3A, the intensities of *Akp3* expression increased significantly in the PK group compared with the control group ( $p < 0.01$ ). Furthermore, the intensities of *Akp6* expression were also increased in both the PK and MK groups compared with the control group ( $p < 0.01$ ,  $p < 0.05$ , respectively) (Fig. 3B). Interestingly, the intensities of PXR expression in both the PK and MK groups were significantly higher than in the control group ( $p < 0.05$ ,  $p < 0.01$ , respectively) (Fig. 3C).

### DISCUSSION

Previously, we reported that several dietary factors such as fat-feeding, vitamin K, and lactose increased IAP activities in rats (12, 15, 24). The high-level activity of IAP, which localizes at the brush border of intes-




Fig. 3. The relative density of PCR products in the mouse jejunum. The diagrams show the relative density of the PCR products. A: The relative density of PCR products for *Akp3*. B: The relative density of PCR products for *Akp6*. C: The relative density of PCR products for PXR. Results are the mean  $\pm$  SE of 4 animals. Significant difference between the PK or MK and control groups (\* $p < 0.05$ , \*\* $p < 0.01$ ). Cont.: control, PK: phylloquinone, MK: menaquinone-4.

nal epithelium cells, suggests the participation of this enzyme in the transport of nutrients.

Recently, we reported that both long-term dietary PK and MK-4 supplementations enhance IAP activity in rats (12). After 3 mo of feeding, we measured IAP activity by dividing it into five segments. In each segment, both PK and MK-4 increased IAP, and the level of IAP activity in the proximal jejunum was significantly

higher than that in the control group ( $p < 0.05$ ) (12). To examine whether the enhancing effect of PK or MK-4 on IAP activity occurs via the intestinal mucosa directly, we performed an oral administration of PK or MK-4 using mice. In the present study, we discovered that the levels of mouse jejunum ALP activity were also significantly increased by the oral administration of PK or MK compared with the control group (Fig. 1B). In addition, we confirmed that the increased ALP isozymes induced by the oral administration of PK or MK showed similar biochemical properties to the typical intestinal type ALP, with no significant differences among these groups (Table 1).

By SDS-PAGE analysis, we detected a 110-kDa ALP enzyme in the duodenum and 90-kDa ALP enzyme in the ileum (Fig. 1D). Both the 110- and 90-kDa ALP enzymes were detected in the jejunum, and the enzymatic activities of these bands were enhanced by the oral administration of PK or MK. The product of the *Akp3* gene was expressed specifically in the duodenum, and the product of *Akp6* was expressed through the small intestine (5). Therefore, we considered that the 110- and 90-kDa ALP enzymes may correspond to the IAPs encoding *Akp3* and *Akp6*, respectively.

We then performed RT-PCR analysis in order to examine the expression of IAPs (*Akp3* and *Akp6*) in the mouse jejunum. PCR products for *Akp3* and *Akp6* mRNAs in the jejunum were detected, and a significant increase in the PCR products of *Akp3* due to the oral administration of PK was observed (Fig. 3A). Moreover, a significant increase in the PCR products of *Akp6* due to the oral administration of PK or MK-4 was also observed (Fig. 3B). These results suggest that the induction of *Akp3* and *Akp6* may be regulated by PK or MK-4.

As the results of RT-PCR, the expression of mRNA for PXR was detected in the duodenum, jejunum and ileum, and it was enhanced significantly in both the PK and MK groups in the jejunum compared with the control group (Fig. 3C). Interestingly, the intestinal segment where the expression of mRNA for PXR by vitamin K had been enhanced corresponded to a similar segment where the expression of mRNA for IAP was enhanced.

Recent studies have revealed that vitamin K functions as a ligand for nuclear steroid and xenobiotic receptor (SXR), as well as a cofactor for  $\gamma$ -carboxylase (25). SXR is expressed predominantly in the liver and intestine, and it regulates transcription such as of cytochrome P450 (CYP) 3A4, which is an enzyme involved in drug metabolism, and MDR1 (multidrug resistance protein 1) which is activated by a diverse array of pharmaceutical agents including taxol, rifampicin, and clotrimazole (26, 27). Ichikawa et al. identified novel SXR target bone-related genes that were regulated by MK-4 in osteoblastic cells using microarray analysis (28). Among extracellular matrix-related genes, they demonstrated that a small leucine-rich repeat proteoglycan, tsukushi, contributes to collagen accumulation (28).

We demonstrated for the first time that the oral administration of vitamin K (both PK and MK-4)

enhanced the level of IAP mRNA expression in the mouse intestine, and PXR mRNA expression also increased. Further studies on the physiological functions of ALP and transcriptional regulation of ALP induction will provide useful data on the novel effect of vitamin K.

#### Acknowledgments

This work was partially supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 20500725).

#### REFERENCES

- 1) Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H. 1988. Structure of the human liver/bone/kidney alkaline phosphatase gene. *J Biol Chem* **263**: 12002–12010.
- 2) Henthorn PS, Raducha M, Kadesch T, Weiss MJ, Harris H. 1988. Sequence and characterization of the human intestinal alkaline phosphatase gene. *J Biol Chem* **263**: 12011–12019.
- 3) Knoll BJ, Rothblum KN, Longley M. 1988. Nucleotide sequence of the human placental alkaline phosphatase gene. Evolution of the 5' flanking region by deletion/substitution. *J Biol Chem* **263**: 12020–12027.
- 4) Sheñ LP, Liu H, Kan YW, Kam W. 1998. 5' Nucleotide sequence of a putative human placental alkaline phosphatase-like gene. *Nucleic Acids Res* **16**: 5694.
- 5) Narisawa S, Hoylaerts ME, Doctor KS, Fukuda MN, Alpers DH, Millán JL. 2007. A novel phosphatase upregulated in *Akp3* knockout mice. *Am J Physiol Gastrointest Liver Physiol* **293**: 1068–1077.
- 6) Lowe M, Strauss AW, Alpers R, Seetharam S, Alpers DH. 1990. Molecular cloning and expression of a cDNA encoding the membrane-associated rat intestinal alkaline phosphatase. *Biochim Biophys Acta* **1037**: 170–177.
- 7) Strom M, Krisinger J, Deluca HE. 1991. Isolation of a mRNA that encodes a putative intestinal alkaline phosphatase regulated by 1,25-dihydroxyvitamin D-3. *Biochim Biophys Acta* **1090**: 299–304.
- 8) Besman M, Coleman JE. 1985. Isozymes of bovine intestinal alkaline phosphatase. *J Biol Chem* **260**: 11190–11193.
- 9) Zhang Y, Shao JS, Xie QM, Alpers DH. 1996. Immunolocalization of alkaline phosphatase and surfactant-like particle proteins in rat duodenum during fat absorption. *Gastroenterology* **110**: 478–488.
- 10) Xie Q, Alpers DH. 2000. The two isozymes of rat intestinal alkaline phosphatase are products of two distinct genes. *Physiol Genomics* **3**: 1–8.
- 11) Harada T, Koyama I, Matsunaga T, Kikuno A, Kasahara T, Hassimoto M, Alpers DH, Komoda T. 2005. Characterization of structural and catalytic differences in rat intestinal alkaline phosphatase isozymes. *FEBS J* **272**: 2477–2486.
- 12) Sogabe N, Maruyama R, Hosoi T, Goseki-Sone M. 2007. Enhancement effects of vitamin K<sub>1</sub> (phylloquinone) or vitamin K<sub>2</sub> (menaquinone-4) on intestinal alkaline phosphatase activity in rats. *J Nutr Sci Vitaminol* **53**: 219–224.
- 13) Vermeer C. 1990. Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase.

- Biochem J* **266**: 625–636.
- 14) Tabb MM, Sun A, Zhou C, Grün E, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B. 2003. Vitamin K<sub>2</sub> regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. *J Biol Chem* **278**: 43919–43927.
  - 15) Goseki-Sone M, Oida S, Imura T, Yamamoto A, Matsumoto HN, Omi N, Takeda K, Maruoka Y, Ezawa I, Sasaki S. 1996. Expression of mRNA encoding intestinal type alkaline phosphatase in rat liver and its increase by fat-feeding. *Liver* **16**: 358–364.
  - 16) Weber K, Pringle JR, Osborn M. 1972. Measurement of molecular weights by electrophoresis on SDS-acrylamide gel. *Methods Enzymol* **26**: 3–27.
  - 17) Kurahashi Y, Yoshiki S. 1972. Electron microscopic localization of alkaline phosphatase in the enamel organ of the young rat. *Arch Oral Biol* **17**: 155–163.
  - 18) Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* **162**: 156–159.
  - 19) Narisawa S, Huang L, Iwasaki A, Hasegawa H, Alpers DH, Millán JL. 2003. Accelerated fat absorption in intestinal alkaline phosphatase knockout mice. *Mol Cell Biol* **23**: 7525–7530.
  - 20) Fowlkes JL, Bunn RC, Liu L, Wahl EC, Coleman HN, Cockrell GE, Perrien DS, Lumpkin CK Jr, Thrailkill KM. 2008. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. *Endocrinology* **149**: 1697–1704.
  - 21) Dehghani H, Narisawa S, Millán JL, Hahnel AC. 2000. Effects of disruption of the embryonic alkaline phosphatase gene on preimplantation development of the mouse. *Dev Dyn* **217**: 440–448.
  - 22) Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. 2005. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. *Hepatology* **42**: 420–430.
  - 23) Goseki-Sone M, Sogabe N, Nakano T, Tanabe R, Haraikawa M, Alpers DH, Komoda T. 2010. Expression of intestinal-type alkaline phosphatase mRNA in liver of Akp3 knockout mice. *J Electrophoresis* **54**: 27–32.
  - 24) Sogabe N, Mizoi L, Asahi K, Ezawa I, Goseki-Sone M. 2004. Enhancement by lactose of intestinal alkaline phosphatase expression in rats. *Bone* **35**: 249–255.
  - 25) Zhou C, Verma S, Blumberg B. 2009. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. *Nucl Recept Signal* **7**: e001.
  - 26) Dussault I, Forman BM. 2002. The nuclear receptor PXR: a master regulator of “homeland” defense. *Crit Rev Eukaryot Gene Exp* **12**: 53–64.
  - 27) Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. 2001. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. *Proc Natl Acad Sci USA* **98**: 3369–3374.
  - 28) Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S. 2006. Steroid and xenobiotic receptor SXR mediates vitamin K<sub>2</sub>-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. *J Biol Chem* **281**: 16927–16934.

*Association of CYP19 Gene Polymorphism  
with Vertebral Fractures in Japanese  
Postmenopausal Women*


Yasuko Koudu, Tsuneko Onouchi,  
Takayuki Hosoi & Toshiyuki Horiuchi

**Biochemical Genetics**

ISSN 0006-2928

Biochem Genet

DOI 10.1007/s10528-011-9483-z

 Springer

Your article is protected by copyright and all rights are held exclusively by Springer Science+Business Media, LLC. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your work, please use the accepted author's version for posting to your own website or your institution's repository. You may further deposit the accepted author's version on a funder's repository at a funder's request, provided it is not made publicly available until 12 months after publication.

## Association of *CYP19* Gene Polymorphism with Vertebral Fractures in Japanese Postmenopausal Women

Yasuko Koudu · Tsuneko Onouchi · Takayuki Hosoi · Toshiyuki Horiuchi

Received: 18 March 2011 / Accepted: 17 November 2011  
© Springer Science+Business Media, LLC 2011

**Abstract** This study investigates aromatase gene polymorphism, which might influence bone strength in terms of mineral density and quality. We explored the relationship between *CYP19* polymorphisms and vertebral fractures in postmenopausal Japanese women. In addition, we compared estrogen and testosterone levels in Japanese postmenopausal women with and without fractures. Osteoporotic postmenopausal women showed higher incidences of vertebral fractures than osteopenic women or women with normal lumbar bone mineral density (L2-4 BMD). Estrogen concentrations in postmenopausal women were associated with BMD; however, no association was found between sex hormone levels and the presence of fractures. The C allele rs2470152 was significantly associated with increased risk of vertebral fractures ( $P = 0.04$ ), whereas none of the *CYP19* polymorphisms showed differences in sex steroid levels between subjects with and without fractures. Allelic variants of aromatase genes appear to interact to influence the risk of vertebral fractures in postmenopausal Japanese women.

**Keywords** Aromatase gene polymorphisms · Vertebral fractures · Postmenopausal women


---

Y. Koudu · T. Horiuchi (✉)  
Department of Endocrinology and Metabolism, Tokyo Metropolitan Toshima Hospital,  
33-1 Sakaecho Itabashiku, Tokyo 173-0015, Japan  
e-mail: t-horiuchi@toshima-hp.jp

T. Onouchi  
Department of Collaborative Research, Teikyo University School of Medicine, Tokyo, Japan

T. Hosoi  
Department of Advanced Medicine, National Center of Geriatrics and Gerontology, Obu, Japan

Published online: 09 December 2011

 Springer

## Introduction

Osteoporosis is caused by multiple factors, including environmental factors (such as calcium intake), exercise, and estrogen levels. The main source of estrogen in postmenopausal women is the aromatization of androgenic precursors, a reaction catalyzed by the cytochrome P450 (CYP) aromatase enzyme, encoded by *CYP19* located on chromosome 15q21.1. It has recently been reported that estrogen levels are genetically determined by aromatase activity (Olson et al. 2007; Haiman et al. 2007; Sowers et al. 2006). In addition, allelic variants of the aromatase gene have been associated with bone mineral density (BMD) and bone fractures (Hong et al. 2007; Masi et al. 2001; Somner et al. 2004). A/G polymorphisms in the 3' untranslated region (UTR) and the I.2 promoter (rs10046 and rs1062033; Rinancho et al. 2005) and an A/G polymorphism in the I.6 promoter rs4775936 (Enjuanes et al. 2006) of the aromatase gene have been studied in relation to osteoporosis and BMD, but the results remain controversial. In addition, an rs2470152 polymorphism in the aromatase gene has been shown to affect serum estrogen levels in Swedish men (Eriksson et al. 2009). Therefore, in order to analyze the association with the risk of vertebral fractures in postmenopausal women, we conducted a cross-sectional study of the interaction between *CYP19* gene polymorphisms and sex steroid hormone levels or risk of vertebral fractures in Japanese postmenopausal women. In this study, we focused on four markers (rs2470152, rs4775936, rs1062033, and rs10046) to clarify the association between polymorphisms in aromatase genes and vertebral fractures.

## Materials and Methods

### Study Subjects

Three hundred sets of genomic DNA and serum samples were provided from the collected samples of the Institute of Medical Sciences, Tokyo University, obtained for tailor-made medicine realization projects. These samples were collected from the various institutions that were members of these projects following the approval of the individual ethics committees. Ethical approval was obtained from the Ethics Committee of the Leading Project for Personalized Medicine in the Institute of Medical Science, University of Tokyo, and the Tokyo Metropolitan Geriatric Hospital. Another 300 DNA samples were collected from women for the purpose of analyzing the relationship between polymorphisms and the etiology of disease in the Japanese population. The samples were provided by the Leading Project for Personalized Medicine of the Ministry of Education, Culture, Sports, Science and Technology, Japan.

The samples were divided into three categories according to the *T* score of the measurement of lumbar spine BMD (L2-4 BMD) by dual energy X-ray absorptiometry (DXA) as defined by the World Health Organization: *T* scores of  $-1.0$  and above were classified as normal BMD, scores of  $-2.5$  to  $-1.0$  were considered osteopenia, and scores below  $-2.5$  were considered osteoporotic.

For assessment of vertebral fractures, anteroposterior and lateral X-ray examinations of the thoracic and lumbar spine were performed. Morphometrically,



a vertebral fracture was defined in terms of the ratio of the anterior height of vertebral body to the posterior height (below 0.75) or the ratio of the center height to the anterior or posterior height (below 0.8). In all cases, the vertebral fractures were evaluated by two groups of radiologists and geriatricians in each institute.

#### Sex Steroid Assay

The serum levels of testosterone ( $T$ ) and estradiol ( $E_2$ ) were measured by mass spectrophotometry (LC-MS/MS). Bioavailable testosterone and estrogen, which includes the free form and the albumin-binding form, were measured by LC-MS/MS (Arai et al. 2010). Serum samples were stored at  $-70^{\circ}\text{C}$  until analyzed. For statistical analysis, the values were transformed into logarithmic form, since the values are exponential and the distributions of  $T$  and  $E_2$  levels were skewed using the raw data.

#### Genotype Analysis

We examined four polymorphisms of *CYP19*: rs1062033, a G/C SNP located at around exon 1.2 (at position chromosome 15, 49335230); rs10046, a T/C SNP located in the 3' UTR (at position chr.15, 49290276); rs4775936, a C/T SNP located in the vicinity of exon 1.6 (at position chr.15, 49323314); and rs2470152, a T/C SNP located in intron 1 (at position chr.15, 49382254). These SNPs were identified by searching the National Center for Biotechnology Information (NCBI) database because they are analyzable by the readily available TaqMan assays used for disease association studies (Applied Biosystems). Polymorphisms in genomic DNA were measured by the TaqMan assay. Age, body mass index, and years since menopause were examined in three SNP genotypes among four *CYP19* markers.

#### Statistical Analyses

Chi-square analysis was used to compare the numbers of osteoporosis, osteopenia, and normal patients by  $T$  scores of L2-4 BMD with and without fractures. Similarly, each parameter was compared among the three genotypes in four *CYP19* markers using ANOVA. The correlation between estradiol levels and L2-4 BMD was shown using Pearson's coefficients. The associations between aromatase gene polymorphisms and vertebral fracture risk were compared by Chi-square analysis using SPSS software.

## Results

#### Bone Density Data

There were significantly more women with fractures than without among patients with osteoporosis ( $T < -2.5$ ;  $P < 0.05$ ), and there was no significant increase in fractures among normal patients or those with osteopenia. There were no differences

in the log estradiol (Log  $E_2$ ) or log testosterone (Log  $T$ ) values between women with fractures and those without fractures (Table 1).

Relationship Between L2-4 BMD and Estrogen level

Log  $E_2$  levels in postmenopausal women were significantly associated with L2-4 BMD ( $r = 0.21$ ,  $p = 0.03$ ; Fig. 1), whereas log  $T$  levels showed no association (data not shown).


Genotype Analysis

When we examined the correlation between the four polymorphisms (rs2470152, rs1062033, rs4775963, and rs10046) and vertebral fractures in postmenopausal women, we found a significant correlation for rs2470152 ( $P = 0.04$ ) but not for the

**Table 1** Bone mineral density of postmenopausal women with and without fractures

$T$ score <sup>a</sup> & sex steroids	Women without fractures (137)	Women with fractures (138)	$P$
$T < -2.5$	18	37	0.015
$-2.5 \leq T < 1.0$	12	13	NS
$-1.0 \leq T$	4	5	NS
Log $E_2$ (pg/ml)	$0.335 \pm 0.383$	$0.327 \pm 0.330$	NS
Log $T$ (ng/dl)	$2.033 \pm 0.367$	$2.067 \pm 0.247$	NS

<sup>a</sup> Bone mineral density was measured in 89 of the 275 subjects  
NS not significant



**Fig. 1** Correlation between log  $E_2$  and L2-4 BMD in postmenopausal women. Estrogen levels were significantly correlated with L2-4 BMD ( $r = 0.21$ ,  $p = 0.03$ )

**Table 2** Correlation of four *CYP19* SNPs with vertebral fractures

SNP	Genotype	Premenopause		<i>P</i>	Postmenopause		<i>P</i>
		Control ( <i>n</i> = 19)	Case ( <i>n</i> = 6)		Control ( <i>n</i> = 136)	Case ( <i>n</i> = 138)	
rs2470152	CC	9	1	0.408	44	47	0.040 <sup>a</sup>
	TC	8	4		56	71	
	TT	2	1		36	20	
rs4775936	CC	5	1	0.712	48	59	0.416
	CT	9	4		68	59	
	TT	5	1		20	20	
rs1062033	CC	4	1	0.693	47	56	0.507
	CG	9	4		64	62	
	GG	6	1		25	20	
rs10046	TT	7	1	0.550	31	26	0.324
	TC	8	4		67	62	
	CC	4	1		38	50	

<sup>a</sup> Only rs2740152 polymorphisms of the aromatase gene showed a significant correlation with vertebral fractures (*P* = 0.04)

**Table 3** Characteristics of postmenopausal Japanese women and three SNPs of rs2470152

Characteristic	Genotype			<i>P</i>
	CC	CT	TT	
Age (years)	72.8 ± 9.3	73.6 ± 8.3	74.3 ± 6.8	NS
Body mass index (kg/m <sup>2</sup> )	22.4 ± 4.6	21.8 ± 4.5	21.1 ± 4.3	NS
Years since menopause	24.2 ± 9.5	24.3 ± 10.3	25.4 ± 11.6	NS
Log <i>E</i> <sub>2</sub> (pg/ml)	0.302 ± 0.319	0.330 ± 0.280	0.307 ± 0.357	NS
Log <i>T</i> (ng/dl)	2.001 ± 0.347	2.067 ± 0.269	2.050 ± 0.313	NS
L2-4BMD (110)	0.753 ± 0.135	0.739 ± 0.157	0.729 ± 0.118	NS
LT score (89)	-2.6 ± 1.2	-2.6 ± 1.3	-3.3 ± 0.8	NS

NS not significant

other three polymorphisms (Table 2). There were no differences in age, body mass index, or years since menopause among the three SNP types in the four *CYP19* markers (Table 3).

## Discussion

We examined the relationship between aromatase-related genes and vertebral fractures by analyzing *CYP19* gene polymorphisms in Japanese women. Among four markers, no differences were found in serum *T* and *E*<sub>2</sub> concentrations in the Japanese postmenopausal women. It is possible that local *E*<sub>2</sub> concentrations are

more important in local tissues rather than serum levels. Bone cells are able to express aromatase and other enzymes required for estrogen synthesis locally (Janssen et al. 1999; Shouzu and Simpson 1998; Watanabe et al. 2004), and aromatase activity in cultured osteoblasts is quantitatively similar to that in adipose stromal cells (Shouzu and Simpson 1998). Thus, estrogen synthesized in bone cells might be important in postmenopausal bone metabolism.

Eriksson et al. (2009) found that genetic variants of rs2470152 in aromatase are associated with  $E_2$  levels, showing that G alleles were correlated with higher serum  $E_2$  levels and BMD in Swedish men than other alleles. Our results, however, showed that the C allele of rs2470152 is associated with vertebral fractures, a finding that suggests that ethnicity, race, and sex differences might influence the results of SNP studies in osteoporosis. The SNP rs2470152 is located in the region of the I.4 promoter (Bulun and Simpson 1994), and it is interesting that the G→A transition of rs2470152 is likely to alter a potential binding site for the binding protein of the transcription factor cAMP response element. The major reason for the discrepancy between our results and those of the Swedish study may be gender differences. The Swedish study focused only on male cohorts. We could not detect any disequilibrium between rs2470152 and the other three markers viewed in HapMap.

*CYP19* SNPs (rs10046) were found to be associated with differences in  $E_2$  levels in the European Prospective Investigation of Cancer-Norfolk (EPIC-Norfolk) cohort study (Dunning et al. 2004). SNP rs10046 explains 1.6% of the variance in the  $E_2:T$  ratio; however, this SNP is not associated with breast cancer risk (Dunning et al. 2004). The rs10046, a T/C SNP located in the 3' UTR, 19 nucleotides downstream from the translation terminus, has been reported to be associated with increased levels of aromatase mRNA expression in tumors (Gruber et al. 2002). In our study, rs10046 was correlated with neither serum  $E_2$  levels nor vertebral fractures. The *CYP19* genotypes demonstrated higher mRNA levels at the rs1062033 locus in postmenopausal osteoporosis. *CYP19* is regulated in a different manner and in different tissues by a hormonally controlled promoter or adipose stromal cell promoter (Mahendroo et al. 1993; Harada et al. 1993). Genetic polymorphisms of *CYP19* might be involved in other processes, such as mRNA stabilization, transcription enhancement, or the post-translational regulation of expression. Neither SNP 1062033 nor rs4775936 was significantly correlated with either serum  $E_2$  levels or vertebral fractures.

We could not detect lower levels of bioavailable serum  $E_2$  by LC-MS/MS in rs2470152; however, another group has shown differences in  $E_2$  levels as measured by RIA according to *CYP19* genotype in a study that included both premenopausal and postmenopausal women (Somner et al. 2004). The discrepancy between the two studies seems to be due to the assay systems used. Bioavailable estrogen levels in postmenopausal women are more relevant than total estrogen levels, which include  $E_2$  bound by sex hormone-binding globulin (SHBG), for bone metabolism. Despite the absence of differences in estrogen levels among the various genotypes, we found that vertebral fracture rates are associated with the *CYP19* genotype in postmenopausal Japanese women in this study. There is much evidence for the role of aromatase activity in bone homeostasis (Miyaura et al. 2001; Oz et al. 2000), and, as previously described, the pharmacological inhibition of aromatase is also associated

with a decrease in BMD and increased risk of fractures (Eastell and Hannon 2005). This indicates that aromatase in local tissues plays roles, both physiologically and pathologically, in bone metabolism.

In conclusion, we provide statistical evidence that the C allele in rs2470152 of the *CYP19* gene is associated with an increased risk of vertebral fractures in postmenopausal Japanese women. Further studies are necessary to detect functional SNPs that induce differences in bone metabolism. Furthermore, we need more participants to detect differences in  $E_2$  levels based on the *CYP19* SNPs of aromatase genes.

**Acknowledgment** This work was supported by the Japanese Osteoporotic Foundation with funds donated by Eli Lilly, Japan, in 2008.

## References

- Arai S, Miyashiro Y, Shibata Y, Kashiwagi B, Tomaru Y, Kobayashi M, Watanabe Y, Honma S, Suzuki K (2010) New quantification method for estradiol in the prostatic tissues of benign prostatic hyperplasia using liquid chromatography–tandem mass spectrometry. *Steroids* 75:13–19
- Bulun SE, Simpson ER (1994) Competitive reverse transcription polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thigh and abdomen of women increase with advantage age. *J Clin Endocrinol Metab* 78:428–432
- Dunning AM, Dowsett M, Healey CS, Tee L, Luben NL, Folkard E, Novik KL, Kelemen L, Ogata S, Pharoah PDP, Easton DF, Day NE, Ponder BAJ (2004) Polymorphism associated with circulating sex hormone levels in postmenopausal women. *J Natl Cancer Inst* 96:936–945
- Eastell R, Hannon R (2005) Long-term effects of aromatase inhibitors on bone. *J Steroid Biochem Mol Biol* 95:151–154
- Enjuanes A, Garcia-Giralto N, Supervia A, Noguez X, Ruiz-Gaspas S, Bustamante M, Mellibovsky L, Grinverg D, Balcells S, Diez-Perez A (2006) A new SNP in a negative regulatory region of the *CYP19A1* gene is associated with lumbar spine BMD in postmenopausal women. *Bone* 38:738–743
- Eriksson AL, Lorentzon M, Vandenput L, Labrie F, Linderson M, Syvanen A, Orwoll ES, Cummings SR, Zmuda JM, Ljuggren O, Karlsson MK, Mellstrom D, Ohlsson C (2009) Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. *J Clin Endocrinol Metab* 94:1033–1041
- Gruber CJ, Tschugguel W, Schneeberger C, Huber JC (2002) Mechanisms of disease: production and actions of estrogens. *N Engl J Med* 346:340–352
- Haiman CH, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burt N, Calle EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Freigelson HS, Hankinson SE, Hayes RB, Henderson BE, Hirshhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Marchand LL, Lenner P, Lund E, Panico S, Peeters PH, Pike MC, Riboli E, Tjonnelland A, Travis R, Trichopoulos D, Wacholder S, Ziegler (2007) Genetic variation at the *CYP19A1* locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. *67:1893-1897*
- Harada N, Utsumi T, Takagi Y (1993) Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. *Proc Natl Acad Sci USA* 90:11312–11316
- Hong X, Hsu Y, Terwedow H, Arguelles LM, Tang G, Liu X, Zhang S, Xu X (2007) *CYP19A1* polymorphisms are associated with bone mineral density in Chinese men. *Hum Genet* 121:491–500
- Janssen JMMF, Bland R, Hewison M, Coughtrie MWH, Sharp S, Arts J, Pols HAP, van Leeuwen JPTM (1999) Estradiol formation by human osteoblasts via multiple pathways: Relation with osteoblast function. *J Cell Biochem* 75:528–537
- Mahendroo MS, Mendelson CR, Simpson ER (1993) Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. *J Biol Chem* 268:19463–19470

- Masi L, Becherini L, Gennari L, Amedei A, Colli E, Falchetti A, Farci M, Silvestri S, Gonnelli S, Brandi ML (2001) Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. *J Clin Endocrinol Metab* 86:2263–2269
- Miyaura C, Toda K, Inada M, Ohshiba T, Matsumoto C, Okada T, Ito M, Shizuta Y, Ito A (2001) Sex and age-related response to aromatase deficiency in bone. *Biochem Biophys Res Commun* 280: 1062–1068
- Olson SH, Bandera EV, Orlov I (2007) Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. *Am J Epidemiol* 165:235–245
- Oz OK, Zerwekh JE, Fisher C, Graves K, Nanu L, Millsaps R, Simpson ER (2000) Bone has a sexually dimorphic response to aromatase deficiency. *J Bone Miner Res* 15:507–514
- Rinancho JA, Zarrabeitia MT, Valero C, Sanudo C, Hernandez JL, Amado JA, Zarabeitia A, Gonzalez-Macias J (2005) Aromatase gene and osteoporosis relationship of ten polymorphic loci with bone mineral density. *Bone* 36:917–925
- Shouzu M, Simpson ER (1998) Aromatase expression of human osteoblast-like cells. *Mol Cell Endocrinol* 139:117–129
- Somner J, McLellan S, Cheung J, Mak YT, Frost ML, Knapp KM, Wierzbicki AS, Wheeler M, Fogelman I, Ralston SH, Hampson GN (2004) Polymorphisms in the P450c17 (17-hydroxylase/17, 20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. *J Clin Endocrinol Metab* 89:344–351
- Sowers MR, Wilson AL, Kardia SR, Chu J, Ferrell R (2006) Aromatase gene (*CYP19*) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. *Am J Med* 119:S23–S30
- Watanabe M, Simpson ER, Pathirage N, Nakajin S, Clyne CD (2004) Aromatase expression in the human fetal osteoblastic cell line SV-HFO. *J Mol Endocrinol* 32:533–545

# Effectiveness of the Salivary Occult Blood Test as a Screening Method for Periodontal Status

Yoshihiro Shimazaki,\* Sumio Akifusa,\* Toru Takeshita,\* Yukie Shibata,\* Yasufumi Doi,† Jun Hata,†† Toshiharu Ninomiya,† Yoichiro Hirakawa,†† Yutaka Kiyohara,‡ and Yoshihisa Yamashita\*

**Background:** Community-based periodontal examinations are not popular despite the high prevalence of periodontal disease among adults. This study examines the effectiveness of a novel salivary occult blood test (SOBT) as a screening method for periodontal status.

**Methods:** Comprehensive health examinations were conducted in adult residents aged  $\geq 40$  years in Hisayama, Fukuoka, Japan; 1,998 subjects, each with  $\geq 20$  teeth, were analyzed. A paper test strip was used to perform the SOBT and was followed by a periodontal examination. Results were ranked as negative or positive. Subjects with  $\geq 15\%$  of teeth with bleeding on probing (BOP) or  $\geq 1$  tooth with a probing depth (PD)  $\geq 4$  mm were defined as having a poor periodontal status. The relationship between the results of the SOBT and periodontal parameters and among other variables was examined.

**Results:** The sensitivity and specificity of the SOBT in screening for poor periodontal status were 0.72 and 0.52, respectively. In a multivariate logistic regression analysis, the results of the SOBT were significantly associated with the proportion of teeth with BOP and the proportion of teeth with PD  $\geq 4$  mm, independent of age, sex, use of antihypertensive medication, use of antidiabetic medication or insulin therapy, and the number of decayed or filled teeth.

**Conclusion:** The SOBT may offer a simple screening method for periodontal status when a thorough periodontal examination is not possible, although it is not sufficiently specific to be a reasonable substitute for a periodontal examination. *J Periodontol* 2011;82:581-587.

## KEY WORDS

Epidemiology; mass screening; periodontal disease; saliva.

\* Section of Preventive and Public Health Dentistry, Division of Oral Health, Growth, and Development, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.

† Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.

‡ Department of Environmental Medicine, Graduate School of Medical Sciences, Kyushu University.

Periodontal disease is prevalent in the adult population.<sup>1</sup> Regular periodontal maintenance therapy had been reported to prevent the progression of tissue destruction in patients with chronic periodontitis, including in patients who smoke.<sup>2</sup> However, in 2004, only 32.7% of Japanese adults aged  $\geq 20$  years had received a dental checkup.<sup>3</sup> A screening test for periodontal status may trigger more frequent dental visits.

A clinical diagnosis of periodontitis requires an evaluation by a trained examiner and evidence of gingival inflammation, loss of connective tissue surrounding the teeth measured by a clinical examination using a periodontal probe, and bone loss detected by radiography.<sup>4</sup> However, it may be difficult to introduce such thorough periodontal examinations in health-maintenance procedures in large-scale populations. A more readily applied periodontal screening method is desirable.

Salivary occult blood tests (SOBTs) have been evaluated primarily as a screening method for gingivitis.<sup>5-9</sup> However, a recently developed SOBT was reported to discriminate subjects with a poor periodontal condition, which was defined as bleeding on probing (BOP) in  $\geq 20\%$  of teeth or a probing depth (PD)  $\geq 6$  mm plus BOP in  $\geq 1$  teeth.<sup>10</sup> Because this SOBT uses a paper strip coated with anti-human hemoglobin

monoclonal antibody, the dietary effects of hemoglobin from other animal species can be avoided.<sup>11</sup>

The aim of the present study is to examine the effectiveness of the new SOBT in screening for periodontal status in a large-scale population.

## MATERIALS AND METHODS

### Study Population

Study participants were recruited in 2007 in the town of Hisayama, which is a suburb of the Fukuoka metropolitan area in southern Japan. The town registry listed 3,810 residents, aged 40 to 79 years; 2,861 (75.1%) of these individuals provided written consent to participate in the study and underwent a comprehensive examination. Dental and medical examinations were performed on 2,669 subjects, including edentulous individuals. There were no pregnant females among the subjects. All subjects who had  $\geq 20$  teeth were included in the study; 671 subjects who had  $< 20$  teeth or who were not able to provide sufficient data were excluded because of the inherent difficulties of properly assessing the periodontal health of these individuals; data on individuals with fewer teeth indicated that they are susceptible to poor periodontal conditions.<sup>12</sup> Thus, the final study sample consisted of 1,998 subjects (888 males and 1,110 females).

The ethics committee of Kyushu University Faculty of Dental Science approved the study design, data collection methods, and procedure for obtaining informed consent (approval 20B-1).

### SOBT

The SOBT<sup>§</sup> was carried out in all subjects between 8:00 am and 11:00 am before the oral health examination. Each subject had refrained from eating and drinking since the previous night but toothbrushing status before saliva collection could not be confirmed. The SOBT immunologically detects human hemoglobin in saliva by using a colloidal gold-labeled anti-human hemoglobin monoclonal antibody. The SOBT was carried out in the sitting position in an examination room. Each subject rinsed his or her mouth for 10 seconds with 3 ml distilled water, which was then spat into a small paper cup. The lower end of the paper test strip containing the colloidal gold-labeled antibody was dipped into the sample. The colloidal gold-labeled antibody dissolved in the solution where it reacted with human hemoglobin in the sample to form an immune complex. The immune complex moved along the test strip by capillary action until it was trapped by an anti-human hemoglobin monoclonal capture antibody immobilized on the upper portion of the strip and resulted in a magenta line. This type of immunochromatography assay is often used as a point-of-care test.<sup>13,14</sup> After 5 minutes, an exam-

iner (YS, SA, TT, and YS and Miki Kawada, Noriaki Kamio, Masaki Yasui, Nao Fukui, and Mikiko Tomioka, Faculty of Dental Science, Kyushu University, Fukuoka, Japan) visually ranked the magenta-stained band according to a color chart as follows: no visible band = negative (manufacturer's reference concentration:  $< 2$   $\mu\text{g/ml}$  human hemoglobin), and a visible magenta band = positive (manufacturer's reference concentration:  $\geq 2$   $\mu\text{g/ml}$  human hemoglobin). The procedure and criterion of the SOBT were explained to each examiner beforehand, although the examiner reliability of the test was not verified.

### Oral Health Examination

Each subject received an oral health examination after the SOBT in a supine position under sufficient artificial light on a normal dental chair or a portable dental chair. Based on the method of the Third National Health and Nutrition Examination Survey,<sup>15</sup> one of nine dentists (YS, SA, TT, and YS and Miki Kawada, Noriaki Kamio, Masaki Yasui, Nao Fukui, and Mikiko Tomioka, Faculty of Dental Science, Kyushu University, Fukuoka, Japan) performed a periodontal examination, based on the standardized probing technique, by using a periodontal probe<sup>||</sup> and examined PDs and clinical attachment loss (AL) on the mesio-buccal and mid-buccal sites of all retained teeth, except for third molars because partially impacted third molars frequently have pseudopockets. Examiner reliability for the PD assessment was verified by an inter-examiner calibration of volunteers who had similar characteristics to the study population; Cohen  $\kappa$  value was  $> 0.8$ , which indicated very good interexaminer agreement. The presence of BOP was defined as teeth exhibiting gingival bleeding within a few minutes after probing periodontal pockets. Because the relation to the SOBT was similar in PDs and clinical AL but slightly stronger in PDs than in clinical AL, this study used PD and BOP as periodontal parameters to examine the relationship between the SOBT and periodontal inflammatory findings.

### General Examination

A blood sample was collected from the antecubital vein in the morning after an overnight fast and analyzed for fasting plasma glucose concentrations. Each participant completed a self-administered questionnaire in advance that included smoking habit (never, former, or current) and medication use; the questionnaire was checked by trained nurses (Miki Inenaga, kanako Mochimatsu and Terumi Kakumori, Hisayama, Fukuoka, Japan). A former smoker was defined as a subject who quit smoking  $> 1$  year before the day of the examination.

§ Perioscreen Sunstar, Osaka, Japan.

|| PCP11, Hu-Friedy, Chicago, IL.



### Statistical Analyses

The percentage of teeth with BOP (%BOP) and the percentage of teeth with PD  $\geq 4$  mm (%PD) were divided into three categories from the distribution of data. The relationship between both periodontal parameters was then examined. Differences were evaluated with the Pearson  $\chi^2$  test, and linearity was evaluated with the Mantel-Haenszel  $\chi^2$  test. Periodontal status was defined based on the following periodontal parameters: poor = %BOP  $\geq 15\%$  or %PD  $> 0\%$ , and healthy = %BOP  $< 15\%$  and %PD = 0%. The relationship between SOBT and periodontal status was examined, and the sensitivity, specificity, and positive and negative predictive values of the SOBT were calculated.

Logistic regression analyses were performed to determine the effects of %BOP and %PD and other variables on the SOBT level, calculating the odds ratio and 95% confidence interval. Age, sex, smoking habit, number of teeth, number of decayed or filled (DF) teeth, fasting plasma glucose level, use of antihypertensive medication, use of lipid-lowering medication, and use of antidiabetic agent or insulin therapy were included as confounding variables in a step-wise multivariate logistic regression analysis.  $P < 0.05$  indicated statistical significance. Statistical analyses were performed using a software program.<sup>¶</sup>

### RESULTS

For 51.9% of subjects, the %PD was 0%. The remaining subjects were divided in one-half:  $> 0\%$  PD  $< 10\%$  and %PD  $\geq 10\%$  (24.1%). The %BOP was  $< 15\%$  in 59.7% of subjects, and the rest of subjects were divided in one-half:  $\geq 15\%$  BOP  $< 30\%$  (20.9%) and  $\geq 30\%$  (19.4%). Table 1 shows the relationship between the %BOP and %PD. The periodontal parameters were positively associated with each other.

Table 2 shows the relationship between SOBT and periodontal status. Using negative or positive as a cutoff, the sensitivity for detecting poor periodontal status was 0.72, and the specificity value was 0.52. The positive and negative predictive values were 0.69 and 0.55, respectively.

Table 3 shows the effects of periodontal parameters and other variables on SOBT. The %BOP, %PD, age, sex, smoking habit, fasting plasma glucose level, use of antihypertensive medication, use of lipid-lowering medication, use of antidiabetic agent or insulin therapy, number of teeth, and number of DF teeth were significantly associated with SOBT by simple logistic regression analyses (Table 3). In a step-wise multivariate logistic regression analysis, %BOP, %PD, age, sex, use of antihypertensive medication, use of antidiabetic agent or insulin therapy, and number of DF teeth were each independently associated with SOBT (Table 3).

### DISCUSSION

This study examined the effectiveness of a recently developed SOBT that uses an anti-human hemoglobin monoclonal antibody as a simple screening method for periodontal status. The test showed a reasonable level of sensitivity in the identification of subjects with gingival bleeding and/or deep periodontal pockets.

Several screening tests without a direct examination of periodontal tissue have been explored. One of these methods, the validity of self-reported periodontal status, was demonstrated.<sup>16-19</sup> Although this method can be easily and inexpensively applied, a single questionnaire item has not been shown to be effective in detecting poor periodontal status.<sup>16,17</sup> Increased efficacy was achieved with a combination of multiple questions and the assessment of conventional risk indicators,<sup>18,19</sup> but cutoffs are difficult to determine, and cross-population generalizations are problematic.

Saliva can be readily and non-invasively obtained, and there are significant opportunities to advance the development of salivary biomarkers for periodontal disease.<sup>20</sup> In a study<sup>21</sup> that examined the level of  $\beta$ -glucuronidase activity in saliva, the sum of sensitivity and specificity to screen the subjects with four or more sites with PD  $\geq 5$  mm was  $\approx 120\%$ . In another study,<sup>22</sup> of the various biochemical markers in saliva examined, the salivary lactate dehydrogenase (LDH) level showed the highest sensitivity (0.66) and specificity (0.67) for the presence of BOP or PD  $\geq 4$  mm. Finally, an examination<sup>23</sup> in pregnant women of a combination of LDH, alkaline phosphatase, and a different SOBT from the one used in the present study showed that the sensitivity and specificity in screening subjects with Community Periodontal Index (CPI) codes 3 or 4 were 89% and 62%, respectively. However, when SOBT was used alone,<sup>23</sup> the sensitivity and specificity were 37% and 91%, respectively. Methods examining various salivary biomarkers are applicable to large populations because they are rapid, and sample collection does not require a dental specialist. However, the instruments and reagents needed for analyses introduce cost and time requirements.

The SOBT used in the present study is an existing saliva test and has some advantages. It can be used on large numbers of subjects without the assistance of dental professionals. The results are available quickly, and the cost is low (the present SOBT would cost  $\approx$ US\$1.3 per capita). In previous studies, a different type of SOBT showed significant correlation with the gingival index<sup>5,6</sup> and with crevicular fluid flow,<sup>6</sup> and another SOBT showed a significant correlation with the PMA index in adolescents<sup>7,8</sup> but not in adults

¶ SPSS version 17.0, IBM, Tokyo, Japan.

**Table 1.****Relationship Between Categories of Proportion of Teeth With BOP and Categories of Proportion of Teeth With PD  $\geq$ 4 mm**

Proportion of Teeth With PD $\geq$ 4 mm	Proportion of Teeth With BOP			P
	<15% (n = 1,193)	$\geq$ 15 to <30% (n = 418)	$\geq$ 30% (n = 387)	
0% (n = 1,036)	801	163	72	<0.001*
>0% to <10% (n = 480)	268	120	92	<0.001†
$\geq$ 10% (n = 482)	124	135	223	

\* Non-linear component calculated using Pearson  $\chi^2$  test.† Linear component calculated using Mantel-Haenszel  $\chi^2$  test.**Table 2.****Relationship Between Saliva Occult Blood Test and Periodontal Status**

Saliva Occult Blood Test	Periodontal Status		
	Poor*	Healthy†	Total
Positive	861	384	1,245
Negative	336	417	753
Total	1,197	801	1,998

\* Proportion of teeth with BOP  $\geq$ 15% or proportion of teeth with PD  $\geq$ 4 mm >0%.† Proportion of teeth with BOP <15% and proportion of teeth with PD  $\geq$ 4 mm = 0%.

>40 years old.<sup>8</sup> These studies<sup>5-8</sup> did not examine the sensitivity or specificity of SOBT or the relationship between SOBT and the presence of deep periodontal pockets. Another SOBT showed a high sensitivity (75.9%) and specificity (90.5%) for >30% BOP in 50 patients at a university dental clinic after stimulation by sulcular toothbrushing for 1 minute; however, when using unstimulated saliva, the sensitivity decreased to 20.7%.<sup>9</sup> Toothbrushing before a screening test may be difficult in a large-scale health examination, and the definition of periodontal status in that study<sup>9</sup> did not evaluate the presence of deep periodontal pockets. In contrast, our results show that SOBT using an anti-human hemoglobin monoclonal antibody had a significant relationship with BOP and deep periodontal pockets and a certain level of effectiveness in screening periodontal status using unstimulated mouthwash saliva in a large-scale adult population.

Although the SOBT showed a relatively favorable sensitivity in identifying subjects suspected to have gingival inflammation, there appeared to be a substantial number of false-negative results. This indicated that it was difficult to discriminate subjects

with periodontal problems by the SOBT alone. In contrast, because the specificity of the test is low, the use of the SOBT might lead to an overestimation of poor periodontal status. The low specificity has several possible causes. Our periodontal examination assessed the mesio-buccal and mid-buccal sites of each tooth. Because deep periodontal pockets are more common at lingual sites than buccal sites,<sup>24</sup> our examination technique might have underestimated the periodontal parameters and, thus, negatively affected the specificity. Because antihypertensive medication and diabetic treatment influenced the SOBT, the presence of hypertension and/or diabetes may promote inflammation of gingival tissue.<sup>25,26</sup> Because the number of DF teeth was also associated with the SOBT, poor oral hygiene due to more caries and restorations, may affect the occult blood reaction. Additionally, it is possible that other factors, such as toothbrushing shortly before examination, recent dental treatment such as tooth extraction or periodontal treatment, and the use of anticoagulant agents, may increase the number of false-positive subjects, although we could not confirm these factors.

According to the Survey of Dental Disease<sup>27</sup> carried out by the Japanese Ministry of Health, Labor, and Welfare in 2005, the proportion of subjects with PD  $\geq$ 4 mm based on the CPI was  $\approx$ 50% in dentate adults aged 40 to 79 years, which was similar to the proportion in the present study. The purpose of this study was to examine the effectiveness of the SOBT as a screening method for periodontal status in a community-based health examination. Considering the high proportion of subjects with deep periodontal pockets and the low proportion of subjects undergoing routine dental checkups,<sup>3</sup> it may be desirable to pick out subjects with periodontal problems by using a sensitive test. The reasons found in previous studies<sup>28-30</sup> for low dental use are wide ranging. In Japan, regular visits to a dentist were associated with the type of household and attention to diet in an adult

**Table 3.**  
**Effect of Periodontal Parameters and Other Variables on Saliva Occult Blood Test in Logistic Regression Analysis**

Independent Variable	Saliva Occult Blood Test		Dependent Variable: Saliva Occult Blood Test (negative = 0; positive = 1)			
	Negative (n = 753)	Positive (n = 1,245)	Crude OR (95% CI)	P	Multivariate OR (95% CI)	P
Proportion of teeth with BOP						
<15%	550	643	1		1	
≥15% to <30%	129	289	1.92 (1.51 to 2.43)	<0.001	1.45 (1.13 to 1.86)	0.004
≥30%	74	313	3.62 (2.74 to 4.48)	<0.001	2.16 (1.58 to 2.94)	<0.001
Proportion of teeth with PD ≥4 mm						
0%	503	533	1		1	
>0% to <10%	165	315	1.80 (1.44 to 2.26)	<0.001	1.41 (1.11 to 1.78)	0.005
≥10%	85	397	4.41 (3.39 to 5.74)	<0.001	2.71 (2.01 to 3.64)	<0.001
Sex (n)						
Female	478	632	1		1	
Male	275	613	1.69 (1.40 to 2.03)	<0.001	1.51 (1.23 to 1.84)	<0.001
Smoking habit (n)						
Never smoker	464	678	1		1	
Former smoker	135	303	1.54 (1.22 to 1.94)	<0.001		
Current smoker	154	264	1.17 (0.93 to 1.48)	0.176		
Fasting plasma glucose level						
<110 mg/dl	623	935	1		1	
≥110 mg/dl	130	310	1.59 (1.26 to 2.00)	<0.001		
Use of antihypertensive medication						
Negative	624	876	1		1	
Positive	129	369	2.04 (1.63 to 2.55)	<0.001	1.46 (1.13 to 1.88)	0.003
Use of lipid-lowering medication						
Negative	670	1,066	1		1	
Positive	83	179	1.36 (1.03 to 1.79)	0.032		
Use of antidiabetic agent or insulin therapy						
Negative	730	1,146	1		1	
Positive	23	99	2.74 (1.73 to 4.36)	<0.001	1.82 (1.11 to 2.96)	0.017
Age (years; median)	56	59	1.03 (1.02 to 1.04)	<0.001	1.02 (1.01 to 1.03)	0.002
Number of teeth (median)	27	26	0.91 (0.88 to 0.94)	<0.001		
Number of DF teeth (median)	15	16	1.02 (1.00 to 1.04)	0.028	1.02 (1.00 to 1.04)	0.024

OR = odds ratio; CI = confidence interval.

population<sup>29</sup> and with a higher number of remaining teeth, younger age, presence of systemic disease, absence of depressive symptoms, and higher education attainment in a  $\geq 70$ -year-old population.<sup>30</sup> In the United States,<sup>28</sup> infrequent dental checkups were associated with being male, having a low income, not having a regular place for dental care, and being anxious about receiving dental care. A previous study<sup>31</sup> found that subjects who did not visit a dentist for routine dental checkups had poor self-perceived oral health. An oral-health examination as part of a routine physical checkup in communities and workplaces may be effective in increasing dental use. Conducting a screening test such as SOBT as a substitute for a periodontal examination might be a way to inform people about their periodontal status and could trigger individuals to visit dental clinics.

This study has several limitations. The partial periodontal examination that probed only buccal sites was insufficient as a gold-standard procedure for determining periodontal condition. Thus, our results may have underestimated the presence of BOP and deep PDs,<sup>24</sup> and this might have elevated the incidence of false-positive subjects and affected the low specificity of SOBT. The definition of poor periodontal status in this study was very broad to pick out many people with symptoms of inflamed periodontal tissue by using a simple SOBT. If more specific and sensitive tests were used, a multilevel definition of periodontal status would have been desirable. Although males showed a greater tendency toward a positive SOBT than females, the cause remains unknown. Comparing saliva sampling by mouthrinsing with sampling using resting saliva may provide useful information. Because we determined the relationship between SOBT and periodontal status using cross-sectional findings, we could not determine the ability of SOBT to detect risks that suggest the future progression of periodontal disease. Finally, the effectiveness of SOBT may differ among target populations with a varying prevalence of periodontal disease.

## CONCLUSIONS

This study shows that SOBT using an anti-human hemoglobin monoclonal antibody may have advantages in identifying subjects suspected of having periodontal problems, although the specificity and sensitivity of SOBT were not very high. However, when a thorough periodontal examination is not possible in a community-based health examination, SOBT may offer a simple screening method for periodontal status and may contribute to increased awareness about oral health and encourage regular dental visits. SOBT can be easily conducted at a low cost; using this test for screening periodontal conditions in school children may be valuable in dental-health education.

## ACKNOWLEDGMENTS

The authors thank Drs. Miki Kawada, Noriaki Kamio, Masaki Yasui, Nao Fukui, and Mikiko Tomioka, who were affiliated with the Faculty of Dental Science, Kyushu University at the time of this study, for assisting in the oral examination. This work was supported by Grants-in-Aid of Scientific Research (20592458 and 22406034) from the Ministry of Education, Science, Sports, and Culture of Japan, Tokyo, Japan, and by the Faculty of Dental Science department budget, Kyushu University. The authors report no conflicts of interest related to this study.

## REFERENCES

1. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet* 2005;366:1809-1820.
2. Fisher S, Kells L, Picard JP, et al. Progression of periodontal disease in a maintenance population of smokers and non-smokers: A 3-year longitudinal study. *J Periodontol* 2008;79:461-468.
3. Ministry of Health, Labour and Welfare of Japan. The National Health and Nutrition Survey in Japan in 2004 (in Japanese). Available at: <http://www.mhlw.go.jp/houdou/2006/05/h0508-1a.html>. Accessed: July 30, 2010.
4. Friedewald VE, Kornman KS, Beck JD, et al. The American Journal of Cardiology and Journal of Periodontology editors' consensus: Periodontitis and atherosclerotic cardiovascular disease. *J Periodontol* 2009;80:1021-1032.
5. Burt BA, Roder DM, Cecil JC, Eklund SA. Saliva-based colorimetric test as an index of gingival inflammation in epidemiologic studies. *Community Dent Oral Epidemiol* 1978;6:290-295.
6. Abbott BH, Caffesse RG. The reliability of a colorimetric test in determining gingival inflammation. *J Periodontol* 1978;49:564-569.
7. Takasuka S, Nakajima I, Sakai K, Miyazawa H, Miyake Y, Akasaka M. Use of the Salivaster salivary occult blood test for the screening of gingivitis in elementary school children and junior high school students (in Japanese). *Shoni Shikagaku Zasshi* 1985;23:103-110.
8. Arakawa H, Udagawa E, Enomoto K, Iizuka Y. An approach to the planning of community health programs for adult periodontal diseases. Screening for periodontal disease using the salivary occult blood test (in Japanese). *Kanagawa Shigaku* 1986;20:503-508.
9. Kopczyk RA, Graham R, Abrams H, Kaplan A, Matheny J, Jasper SJ. The feasibility and reliability of using a home screening test to detect gingival inflammation. *J Periodontol* 1995;66:52-54.
10. Ohshima M, Fujikawa K, Kumagai K, et al. Evaluation of a novel test paper strip method for detecting occult blood in saliva as a screening test for periodontal disease (in Japanese). *J Jpn Soc Periodontol* 2001;43:416-423.
11. Ohshima M, Suzuki K, Eda M, et al. An immunological test using anti-human hemoglobin monoclonal antibody for detection of occult blood in saliva—comparison with peroxidase method (in Japanese). *J Jpn Soc Periodontol* 1997;39:273-280.
12. Locker D, Leake JL. Risk indicators and risk markers for periodontal disease experience in older adults living independently in Ontario, Canada. *J Dent Res* 1993;72:9-17.